MANDALMED, INC.

Basic Information

665 3rd Street
Suite 250
SAN FRANCISCO, CA, 94107-1953

http://www.mandalmed.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 031636660
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: 4


  1. Protein inhibitor of galectin-3 to limit fibrosis after myocardial infarction

    Amount: $299,958.00

    DESCRIPTION (provided by applicant): The wound-healing response of the human body to injuries involves induction of fibrosis, which is a dynamic scarring process. When fibrosis occurs in internal orga ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Model of the Human Testis for Reproductive Toxicology

    Amount: $250,000.00

    DESCRIPTION (provided by applicant): More than 87,000 chemicals have been developed and distributed over the past 50 years. The vast majority of these have not been tested for potential toxic effects ...

    SBIR Phase I 2011 Department of Health and Human Services
  3. Preclinical Testing of Galectin-3C for Multiple Myeloma

    Amount: $363,936.00

    DESCRIPTION (provided by applicant): The overall goal is development of a novel human protein, Galectin-3C, as a treatment for multiple myeloma (MM) that can be given with other agents to increase the ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. Human Sertoli Cell Model for Study of Male Reproductive Function and Toxicity

    Amount: $255,200.00

    DESCRIPTION (provided by applicant): The overall goal of the Phase I research is to develop a three-dimensional model of the blood-testis barrier (BTB) consisting of primary human Sertoli cells cultur ...

    SBIR Phase I 2007 Department of Health and Human Services
  5. NO-donor/SOD-mimetics for diabetic nephropathy

    Amount: $134,000.00

    DESCRIPTION (provided by applicant): Vascular disease is the principal cause of morbidity and mortality in patients with diabetes, leading to nephropathy, retinopathy, neuropathy, and ischemic disease ...

    SBIR Phase I 2005 Department of Health and Human Services
  6. Novel Ex Vivo Gene Therapy for Spinal Cord Injury

    Amount: $749,980.00

    DESCRIPTION (provided by applicant): There are approximately 10,000 traumatic spinal cord injuries in the United States each year. The average age of injury is 31 years. The majority (90%) of individu ...

    SBIR Phase II 2003 Department of Health and Human Services
  7. NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY

    Amount: $155,695.00

    DESCRIPTION (provided by applicant): The goal of the Phase I research is to develop ex vivo gene therapy that will achieve long-term, localized delivery of human neurotrophin-3 (hNT-3) i ...

    SBIR Phase I 2002 Department of Health and Human Services
  8. Novel Treatment for Breast Cancer: Truncated Galectin-3

    Amount: $236,893.00

    DESCRIPTION (provided by applicant): Despite the available treatments breast cancer ranks second as the cause of death from cancer in women pri ...

    SBIR Phase I 2001 Department of Health and Human Services
  9. N/A

    Amount: $142,130.00

    N/A

    SBIR Phase I 2000 Department of Health and Human Services
  10. GALECTIN 1 FOR MULTIPLE SCLEROSIS

    Amount: $135,801.00

    N/A

    SBIR Phase I 1999 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government